Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Tonix Pharma (TNXP).
Tonix Pharmaceuticals Holding Corp. has revealed promising results from animal studies on TNX-1500, a potential treatment with an antibody designed for monthly dosing, evidenced by a projected three-week half-life in humans. The company is optimistic as the engineered protein met its design goals in terms of activity and tolerability, and is gearing up for a Phase 1 trial in the third quarter of 2024. These developments suggest a significant stride in the pharmaceutical firm’s product pipeline, with implications for its competitive position and future market opportunities.
See more data about TNXP stock on TipRanks’ Stock Analysis page.